Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15830723 | 0.73 | PARP10 (0.44) | BRD4 | |
| SCHEMBL17372865 | 0.73 | EZH2 (0.50) | EZH2 | |
| SCHEMBL20499462 | 0.70 | NOTUM (0.41) | — | |
| SCHEMBL29408704 | 0.70 | EZH2 (1.00) | EZH2 | |
| SCHEMBL29408702 | 0.70 | EZH2 (1.00) | EZH2 | |
| SCHEMBL15813960 | 0.70 | EZH2 (1.00) | EZH2 | |
| SCHEMBL17382971 | 0.69 | EZH2 (1.00) | EZH2 | |
| SCHEMBL31026213 | 0.68 | PARP10 (0.44) | — | |
| SCHEMBL15813831 | 0.68 | PARP10 (0.44) | — | |
| SCHEMBL15813912 | 0.68 | PARP1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266542-B2 | EZH2 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266542-B2 | EZH2 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180265517-A1 | EZH2 Inhibitors | Mirati Therapeutics, Inc. | 2018-09-20 | — | — | US | disclosed |
| US-9255104-B2 | Cyclopropyl modulators of P2Y12 receptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265517-A1 | EZH2 Inhibitors | EZH2, BMI1, EED | EZH2 1/4885NR3C1 465/4885PGR 1671/4885 |
| US-10266542-B2 | EZH2 inhibitors | EZH2, BMI1, EED | EZH2 1/4885NR3C1 465/4885PGR 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.